Amgen Inc (NASDAQ:AMGN) Big Money Q1 2018 Sentiment at 0.88

June 26, 2018 - By Jeanette Garcia

Amgen Inc. (NASDAQ:AMGN) Corporate Logo

Positions for Amgen Inc (NASDAQ:AMGN)

“Big money sentiment for Amgen Inc (NASDAQ:AMGN) in Q1 2018 decreased to 0.88, SEC filings reveal. That’s down -0.34, from 2017Q4’s 1.22. 549 funds started new or increased equity positions, while 624 sold and decreased their stakes in Amgen Inc so the sentiment is negative. These funds own 502.72 million shares, that’s down from 551.71 million shares in 2017Q4. Funds holding Amgen Inc in top 10 decreased from 48 to 45 for a decrease of 3. 67 Investors Sold All; 557 Reduced Holdings; 435 increased holdings while 114 funds bought holdings.

Largest Amgen Inc Investors

As of Q1 2018 Krensavage Asset Management Llc has 10.81% invested in Amgen Inc. Amgen Inc’s shareholder Valueworks Llc owns 51,610 shares as of Q1 2018. Also, Smead Capital Management Inc. reported 742,558 shares in Amgen Inc equivalent to 6.13% of its US long equity exposure. Merriman Wealth Management Llc revealed 132,831 shares position in Amgen Inc. The Pennsylvania-based fund Coho Partners Ltd. looks positive on Amgen Inc, possessing 1.06 million shares.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.The firm is worth $122.15 billion. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.60.48 is the P/E ratio. The companyÂ’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism ; and Erenumab for the prevention of migraine.

AMGN touched $184.6 during the last trading session after $0.76 change.Currently Amgen Inc. is uptrending after 14.68% change in last June 26, 2017. AMGN has also 1.46M shares volume. The stock outperformed the S&P 500 by 2.11%.

Amgen Inc. (NASDAQ:AMGN) is anticipated to report earnings on July, 24., as reported by Faxor. Analysts predict $3.52 EPS, which is $0.25 up or 7.65 % from 2017’s $3.27 EPS. In case of $3.52 EPS AMGN’s profit could hit $2.33 billion. 1.44 % EPS growth is what analysts predict. $3.47 EPS was revealed for last quarter.

Sheets Smith Wealth Mngmt holds 0.21% or 5,007 shs in its capital. Virginia Retirement Systems Et Al holds 0.16% of its capital in Amgen Inc. (NASDAQ:AMGN) for 78,828 shs. Captrust Fin Advisors reported 7,293 shs or 0.07% of all its holdings. West Chester Advsr invested 1.53% of its capital in Amgen Inc. (NASDAQ:AMGN). Nelson Roberts Ltd holds 0.11% of its capital in Amgen Inc. (NASDAQ:AMGN) for 2,392 shs. First reported 40,159 shs. Flossbach Von Storch Ag has invested 0.11% in Amgen Inc. (NASDAQ:AMGN). Guardian Lp, a Ontario – Canada-based fund reported 61,806 shs. Park Oh has 8,605 shs for 0.09% of their capital. Bingham Osborn Scarborough Ltd Liability Corporation owns 2,687 shs. Liberty Mutual Grp Incorporated Asset owns 29,082 shs for 0.15% of their capital. Pittenger And Anderson Incorporated stated it has 27,435 shs. Mckinley Carter Wealth Svcs Inc owns 2,508 shs for 0.14% of their capital. Css Limited Liability Corporation Il stated it has 14,295 shs. Becker Capital Mngmt invested in 0.67% or 117,971 shs.

Amgen Inc. registered $1.65 million net activity with 0 buys and 6 sales since January 16, 2018.

Amgen Inc. (NASDAQ:AMGN) Ratings Coverage

A total of 13 analysts rate Amgen Inc (NASDAQ:AMGN) as follows: 6 “Buy”, 7 “Hold” and 0 “Sell”. Тherefore 46% are bullish. (NASDAQ:AMGN) has 16 ratings reports on 26 Jun 2018 according to StockzIntelligence. On Friday, February 2 Credit Suisse maintained Amgen Inc. (NASDAQ:AMGN) rating. Credit Suisse has “Neutral” rating and $194 target. The stock rating was maintained by Mizuho with “Buy” on Monday, February 12. On Wednesday, April 25 the rating was maintained by Morgan Stanley with “Overweight”. In Thursday, February 1 report Cowen & Co maintained it with “Buy” rating and $204.0 target. In Tuesday, January 23 report Argus Research upgraded it to “Buy” rating and $220 target. On Friday, February 2 Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) with “Overweight” rating. In Wednesday, January 24 report JP Morgan maintained the stock with “Neutral” rating. On Thursday, January 18 the stock has “Buy” rating by Piper Jaffray. On Thursday, April 5 the firm earned “Equal-Weight” rating by Barclays Capital. On Thursday, February 1 the firm has “Buy” rating given by Piper Jaffray.

For more Amgen Inc. (NASDAQ:AMGN) news published briefly go to: Nasdaq.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” published on June 24, 2018, “Amgen Should Rebound On Aimovig And Kyprolis Revenue” on June 20, 2018, “The Best Dividend-Paying Biotech Stocks For Your Portfolio” with a publish date: June 25, 2018, “Amgen Has Me Worried Therefore Selling Calls” and the last “EC grants full approval for Amgen’s Blincyto” with publication date: June 19, 2018.

Amgen Inc. (NASDAQ:AMGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.